DBV Technologies | DBVT - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amarin USD 20.81M 13K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
DBV Technologies USD 235.6M 98.78M 2025-12
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Galectin Therapeutics USD 61K 0 2023-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Incyte USD 199.95M 1.49M 2026-03
Insmed USD 216.52M 2.27M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Neurocrine Biosciences USD 100.6M 500K 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03